Lung infection is the leading cause of morbidity and mortality in cystic fibrosis (CF) patients
and is mainly dominated by Pseudomonas aeruginosa. Treatment of CF-associated lung …

With the increasing recognition of biofilms in human disease, the development of novel
antimicrobial therapies is of critical importance. For example, in patients with cystic fibrosis …

Objectives Pseudomonas aeruginosa is a common cause of pneumonia in patients with
cystic fibrosis with the property to generate multidrug resistance against clinically used …

Background Treatment of cystic fibrosis-associated lung infections is hampered by the
presence of multi-drug resistant pathogens, many of which are also strong biofilm producers …

Greater than 90% of lung infections in cystic fibrosis (CF) patients are caused by
Pseudomonas aeruginosa, and the majority of these patients subsequently die from lung …

The emergence of multidrug-resistant pathogens renders antibiotics ineffective in the
treatment of lung infections in patients with cystic fibrosis (CF). Designed antimicrobial …

Pseudomonas aeruginosa is a major cause of chronic lung infections in cystic fibrosis (CF)
patients. The ability of the bacterium to form biofilms and the presence of a thick and …

Objectives Chronic infections with the opportunistic pathogen Pseudomonas aeruginosa are
responsible for the majority of the morbidity and mortality in patients with cystic fibrosis (CF) …

Cystic fibrosis (CF) patients often acquire chronic respiratory tract infections due to
Pseudomonas aeruginosa and Burkholderia cepacia complex (Bcc) species. In the CF lung …

There is a clear need for new antimicrobials to improve current treatment of chronic lung
infection in people with cystic fibrosis (CF). This study determined the activities of …